- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Access Insights 2023: Bill Roth Discusses Top Trends Impacting Executives in 2023
Bill Roth provides his thoughts on top trends impacting pharma's top executives.
In an interview with Nicholas Saraceno, Bill Roth, SVP, Managing Partner, Blue Fin Group, discusses top trends impacting executives in 2023 and what it will lead into for 2024.
Roth: I think what people are realizing is that they can't run their commercial strategies and silos anymore. They can't allow marketing to do their thing. It's the alignment of those functions that matter so much. That is actually harder than you'd think.
The base function of what I think our everyday roles are is that we align the groups. We help marketing understand what access means and vice versa. From there, they are trying to get their heads around PBMs, removal of the AmCap, the IRA, how you balance all of the discounts and fees, and try to drive utilization. There is no recipe that's out there.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
